Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis
Author:
Publisher
Elsevier BV
Subject
General Medicine
Reference61 articles.
1. Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates;Wong;Ann Transl Med,2014
2. The antibody-drug conjugate target landscape across a broad range of tumour types;Moek;Ann Oncol,2017
3. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies;Tarantino;CA A Cancer J Clin,2022
4. First-in-human HER2-targeted bispecific antibody KN026 for the treatment of patients with HER2-positive metastatic breast cancer: results from a phase I StudyHER2-targeted bispecific antibody KN026 in MBC;Zhang;Clin Cancer Res,2022
5. LBA45 Primary data from DESTINY-Lung 01: a phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC);Li;Ann Oncol,2021
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody–drug conjugate–resistant HER2-overexpressing breast cancer;Journal of Experimental & Clinical Cancer Research;2024-08-21
2. HER2-CD3-Fc Bispecific Antibody-Encoding mRNA Delivered by Lipid Nanoparticles Suppresses HER2-Positive Tumor Growth;Vaccines;2024-07-21
3. Incidence of antibody–drug conjugate-related fatigue in patients with breast cancer: A systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2024-04
4. Pioneering the Way: The Revolutionary Potential of Antibody–Drug Conjugates in NSCLC;Current Treatment Options in Oncology;2024-03-23
5. Incidence and risk of fatal adverse events in cancer patients treated with HER2-targeted antibody-drug conjugates: a systematic review and meta-analysis of randomized controlled trials;BMC Cancer;2023-10-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3